Floatz logo

Npt 2042

Epilepsy, Absence

NeuroPro Therapeutics, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Epilepsy, Absence cohort.

Asset / SponsorPhaseRating
Brivaracetam Film-Coated
UCB Biopharma SRL
Phase 3BB
Brivaracetam
UCB Biopharma SRL
Phase 3BB
Ethosuximide
Children's Hospital Medical Center, Cincinnati
Phase 3BB
LAMOTRIGINE
Children's Hospital Medical Center, Cincinnati
Phase 3BB
Valproic Acid
Children's Hospital Medical Center, Cincinnati
Phase 3B
Topamax
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
FLUNARIZINE HCL
University of British Columbia
Phase 2CCC
Bmb-101
Bright Minds Biosciences Pty Ltd
Phase 2NR

Same molecule, other indications

Npt 2042 is also rated in:

generalized epilepsyDormant
CCC
Indicative ·
53 / 100
View asset →
Epilepsy IntractableDormant
CCC
Indicative ·
52 / 100
View asset →
epilepsyDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →